KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?

Journal of Global Antimicrobial Resistance

Volumn 15, Issue , 2018, Pages 173-177

  Antochevis, Laura C ^a,b   Magagnin, Cibele M ^a,b   Nunes, Aline G ^a   Goulart, Taíse M ^a   Martins, Amanda S ^a   Cayô, Rodrigo ^c   Gales, Ana C ^c   Barth, Afonso L ^a   Zavascki, Alexandre P ^a,d,e  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Fleury   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e HOSPITAL MOINHOS DE VENTO   (Brazil)

Author keywords

Aminoglycosides; Colistin; Klebsiella pneumoniae carbapenemase; Polymyxins; Resistance; Tigecycline

Indexed keywords

AMIKACIN; BACTERIAL DNA; BETA LACTAMASE; CARBAPENEM; CARBAPENEMASE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; POLYMYXIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BRAZILIAN; CLONE; CONTROLLED STUDY; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; TERTIARY CARE CENTER; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; BLOOD; BRAZIL; DRUG EFFECT; ENZYMOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BRAZIL; DRUG RESISTANCE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 85055262411     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2018.07.011     Document Type: Article

References (35)

1. Bartolleti, F., Seco, B.M., Capuzzo Dos Santos, C., Felipe, C.B., Lemo, M.E., Alves da, T.S., et al. Polymyxin B resistance in carbapenem-resistant Klebsiella pneumoniae, São Paulo, Brazil. Emerg Infect Dis 22 (2016), 1849–1851.
2. KPC. Antimicrob Agents Chemother, 61, 2017 pii: e02610-16.
3. Braun, G., Cayo, R., Matos, A.P., Fonseca, J.M., Gales, A.C., Temporal evolution of polymyxin B-resistant Klebsiella pneumoniae clones recovered from blood cultures in a teaching hospital during a 7-year period. Int J Antimicrob Agents 51 (2017), 522–527.
4. Kontopidou, F., Giamarellou, H., Katerelos, P., Maragos, A., Kioumis, I., Trikka-Graphakos, E., et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 20 (2014), O117–O123.
5. Monaco, M., Giani, T., Raffone, M., Arena, F., Garcia-Fernandez, A., Pollini, S., et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill, 19, 2014 pii: 20939.
6. Zavascki, A.P., Klee, B.O., Bulitta, J.B., Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther 15 (2017), 519–526.
7. Dixit, D., Madduri, R.P., Sharma, R., The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12 (2014), 397–400.
8. Monteiro, J., Widen, R.H., Pignatari, A.C., Kubasek, C., Silbert, S., Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 67 (2012), 906–909.
9. Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing. 28th ed., 2018, CLSI, Wayne, PA CLSI supplement M100.
10. European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical MIC breakpoints. http://www.eucast.org. [Accessed 2 April 2018].
11. US Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters (v3.0). http://www.uscast.org. [Accessed 2 April 2018].
12. ® (tigecycline). http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021821s039lbl.pdf. [Accessed 2 April 2018].
13. Diancourt, L., Passet, V., Verhoef, J., Grimont, P.A., Brisse, S., Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43 (2005), 4178–4182.
14. Daikos, G.L., Tsaousi, S., Tzouvelekis, L.S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58 (2014), 2322–2328.
15. Tumbarello, M., Trecarichi, E.M., De Rosa, F.G., Giannella, M., Giacobbe, D.R., Bassetti, M., et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70 (2015), 2133–2143.
16. Giannella, M., Trecarichi, E.M., Giacobbe, D.R., De Rosa, F.G., Bassetti, M., Bartoloni, A., et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 51 (2018), 244–248.
17. Mattioli, F., Fucile, C., Del Bono, V., Marini, V., Parisini, A., Molin, A., et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol 72 (2016), 839–848.
18. Cojutti, P., Sartor, A., Righi, E., Scarparo, C., Bassetti, M., Pea, F., Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother, 61, 2017 pii: e00794-17.
19. Pea, F., Della Siega, P., Cojutti, P., Sartor, A., Crapis, M., Scarparo, C., et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. Int J Antimicrob Agents 49 (2017), 255–258.
20. Sandri, A.M., Landersdorfer, C.B., Jacob, J., Boniatti, M.M., Dalarosa, M.G., Falci, D.R., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57 (2013), 524–531.
21. Tran, T.B., Velkov, T., Nation, R.L., Forrest, A., Tsuji, B.T., Bergen, P.J., et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. Int J Antimicrob Agents 48 (2016), 592–597.
22. Xie, J., Roberts, J.A., Alobaid, A.S., Roger, C., Wang, Y., Yang, Q., et al. Population pharmacokinetics of tigecycline in critically ill patients with severe infections. Antimicrob Agents Chemother, 61, 2017 pii: e00345-17.
23. Shields, R.K., Clancy, C.J., Press, E.G., Nguyen, M.H., Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 60 (2016), 3187–3192.
24. Livermore, D.M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., Woodford, N., What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 37 (2011), 415–419.
25. Chen, A., Smith, K.P., Whitfield, B.A., Zucchi, P.C., Lasco, T.M., Bias, T.E., et al. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagn Microbiol Infect Dis 88 (2017), 365–367.
26. Sader, H.S., Castanheira, M., Farrell, D.J., Flamm, R.K., Mendes, R.E., Jones, R.N., Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014). Int J Antimicrob Agents 48 (2016), 144–150.
27. Tang, H.J., Lai, C.C., Chen, C.C., Zhang, C.C., Weng, T.C., Chiu, Y.H., et al. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: combination of tigecycline or doxycycline and gentamicin or amikacin. J Microbiol Immunol Infect(March), 2016, 10.1016/j.jmii.2016.03.003 [Epub ahead of print].
28. Dalmolin, T.V., Martins, A.F., Zavascki, A.P., de Lima-Morales, D., Barth, A.L., Acquisition of the mcr-1 gene by a high-risk clone of KPC-2-producing Klebsiella pneumoniae ST437/CC258, Brazil. Diagn Microbiol Infect Dis 90 (2018), 132–133.
29. Braun, G., Cayô R., Matos, A.P., de Mello Fonseca, J., Gales, A.C., Temporal evolution of polymyxin B-resistant Klebsiella pneumoniae clones recovered from blood cultures in a teaching hospital during a 7-year period. Int J Antimicrob Agents 51 (2018), 522–527.
30. Pitout, J.D.D., Nordmann, P., Poirel, L., Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59 (2015), 5873–5884.
31. Lomonaco, S., Crawford, M.A., Lascols, C., Timme, R.E., Anderson, K., Hodge, D.R., et al. Resistome of carbapenem- and colistin-resistant Klebsiella pneumoniae clinical isolates. PLoS One, 13, 2018, e0198526.
32. Harada, S., Ishii, Y., Saga, T., Aoki, K., Tateda, K., Molecular epidemiology of Klebsiella pneumoniae K1 and K2 isolates in Japan. Diagn Microbiol Infect Dis 91 (2018), 354–359, 10.1016/j.diagmicrobio.2018.03.010.
33. Moubareck, C.A., Mouftah, S.F., Pál, T., Ghazawi, A., Halat, D.H., Nabi, A., et al. Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Int J Antimicrob Agents 52 (2018), 90–95, 10.1016/j.ijantimicag.2018.03.003.
34. NDM-5 in China. Front Microbiol, 8, 2017, 335.
35. Taniguchi, Y., Maeyama, Y., Ohsaki, Y., Hayashi, W., Osaka, S., Koide, S., et al. Co-resistance to colistin and tigecycline by disrupting mgrB and ramR with IS insertions in a canine Klebsiella pneumoniae ST37 isolate producing SHV-12, DHA-1 and FosA3. Int J Antimicrob Agents 50 (2017), 697–698.